Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Posted on Oct 10, 2022

Today, Airfinity is launching a brand new surveillance solution designed to equip decision makers with a holistic overview of the global infectious disease risk situation, from over 160 viruses, fungi, parasitic and bacterial diseases.

Key Product Features:

Daily Alerts: Near real-time risk assessment of outbreaks worldwide, including any new changes in cases or any new variants detected.

Weekly Reports: Biorisk Report: provides an overview of global outbreaks within the context of wider environmental changes, deep dive analysis & forecasts. COVID-19 Pandemic: provides detailed epidemiological analysis of the COVID-19 situation, including variant spread.

Platform: A Global Outbreaks Tracker, real time epidemiological analysis, and monitoring (including COVID-19 and Monkeypox), all with extensive filtering options and downloadable data. Learn more about Airfinity Biorisk and request more information here.

More Insights From Airfinity

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022

Airfinity launches Influenza and RSV Commercial solutions

Jul 6, 2022